Clinical Trials Search | Clareo Health

Showing 1-1 of 1 trials

Study of GC012F, CAR-T Therapy Targeting CD19 and BCMA in Chinese Participants With Relapsed or Refractory AL Amyloidosis

NCT07250269

This is a Phase 1b open-label, multicenter, non-randomized study of GC012F, a CD19/BCMA dual CAR T cell therapy, in adult participants with relapsed/refractory AL amyloidosis.

Relapsed/Refractory AL Amyloidosis

Gracell Biotechnologies (Shanghai) Co., Ltd.9 participantsStarted Oct 2025

Beijing, China • Beijing, China • Beijing, China +6 more locations

Data from ClinicalTrials.govTerms

Filters

Filters

Study of GC012F, CAR-T Therapy Targeting CD19 and BCMA in Chinese Participants With Relapsed or Refractory AL Amyloidosis

Study of GC012F, CAR-T Therapy Targeting CD19 and BCMA in Chinese Participants With Relapsed or Refractory AL Amyloidosis